MedTrace Logo

A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

NCT05658146 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2023-10-11

No results posted yet for this study

Summary

The purpose of this study is to assess the effects on the single-dose drug levels of mavacamten in healthy participants.

Conditions

  • Healthy Participants

Interventions

DRUG

Mavacamten Capsule 1

Specified dose on specified days

DRUG

Mavacamten Capsule 2

Specified dose on specified days

DRUG

Mavacamten Capsule 3

Specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-06
Primary Completion
2023-07-05
Completion
2023-07-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05658146 on ClinicalTrials.gov